P/B
6,7
Insulet
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
$9.6B
Market Cap • 9/14/2026
2000
(26 years)
Founded
2007
(19 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
S&P500 Participant
Index Composite • 2026
Valuation
P/S
3,1
P/EBITDA
15,5
P/OCF
18,7
P/FCF
32,5
P/E
25,8
BVPS
20,2
EPS
5,4
Market Cap
Market Cap
9,6B
EV
10B
EV/Revenue
3,3
EV/EBITDA
16,2
EV/EBIT
19,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
3,4%
Total Yield
3,4%
Payout
0%
Retained Earnings
473,5M
Profitability
Gross Margin
71,1%
EBITDA Margin
20,1%
EBIT Margin
16,9%
Net Margin
12,3%
D&A/EBITDA
0%
R&D/Revenue
11,3%
Capex/Revenue
7,1%
Capex/D&A
219%
Capex/OCF
42,5%
SBC/OCF
15,2%
% PPE
27,1%
% Goodwill
1,6%
ROE
26%
ROIC
33,6%
Growth
CAGR Revenue 5Y
25,1%
CAGR Op. Income 5Y
54,2%
CAGR OCF 5Y
52,3%
Leverage
N.D./EBITDA
0,7
Debt/Equity
0%
Current Ratio
2,5
Quick Ratio
0,7
Interest Coverage
878,7%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!